Article info
PDFArrhythmias and sudden death
Original research
Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation
- Correspondence to Professor Olivier Hanon, Service de Gérontologie, Hôpital Broca, 75013 Paris, France; olivier.hanon{at}aphp.fr
Citation
Bleeding risk with rivaroxaban compared with vitamin K antagonists in patients aged 80 years or older with atrial fibrillation
Publication history
- Received July 29, 2020
- Revised October 19, 2020
- Accepted October 21, 2020
- First published December 1, 2020.
Online issue publication
January 08, 2022
Article Versions
- Previous version (8 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.